# Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

> **NCT04635683** · PHASE1 · WITHDRAWN · sponsor: **Yazeed Sawalha**

## Conditions studied

- Recurrent B-Cell Non-Hodgkin Lymphoma
- Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Recurrent Follicular Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Grade 3a Follicular Lymphoma
- Recurrent Lymphoplasmacytic Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Marginal Zone Lymphoma
- Recurrent Nodal Marginal Zone Lymphoma
- Recurrent Splenic Marginal Zone Lymphoma
- Recurrent Waldenstrom Macroglobulinemia
- Refractory B-Cell Non-Hodgkin Lymphoma
- Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Refractory Follicular Lymphoma
- Refractory Grade 1 Follicular Lymphoma
- Refractory Grade 2 Follicular Lymphoma
- Refractory Grade 3a Follicular Lymphoma
- Refractory Lymphoplasmacytic Lymphoma
- Refractory Mantle Cell Lymphoma
- Refractory Marginal Zone Lymphoma
- Refractory Nodal Marginal Zone Lymphoma
- Refractory Splenic Marginal Zone Lymphoma
- Refractory Waldenstrom Macroglobulinemia

## Interventions

- **DRUG:** Lenalidomide
- **BIOLOGICAL:** Ublituximab
- **DRUG:** Umbralisib

## Key facts

- **NCT ID:** NCT04635683
- **Lead sponsor:** Yazeed Sawalha
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-09-30
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Investigational Drug removed from the market
- **Last updated:** 2022-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04635683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04635683, "Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04635683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*